Ebola Toll in DR Congo Climb to 1,561 Cases with 506 Fatalities as Health Workers Threaten Strike

Core developments

The Ministry of Health in the Democratic Republic of Congo announced that the total number of laboratory‑confirmed Ebola cases has risen to 1,561, with 506 deaths recorded to date. The figures were disclosed in a statement cited by Reuters and echoed by other news agencies Reuters, WTVB, U.S. News & World Report and سانا. The uptick reflects continued transmission in the eastern provinces where the virus has resurfaced for the third time since 2018.

Health‑care workers on the front lines have warned that the mounting caseload is stretching already‑strained treatment centres. According to a report from SRN News, staff members have signaled a possible strike if protection measures are not improved, citing fatigue, insufficient personal protective equipment and the emotional toll of repeated outbreaks SRN News. While the article does not quote individual names, it notes that the threat of industrial action adds a new layer of urgency to the response.

Amid the crisis, a biotech firm called NanoViricides announced progress on an experimental oral‑gummy formulation, NV‑387, that is slated for a clinical trial in the DRC. The company says the gummy could simplify administration compared with intravenous therapies, a development highlighted by Stock Titan Stock Titan. No efficacy data have been released, but the move signals a push to diversify the therapeutic toolbox against Ebola.

Why it matters

Ebola remains one of the world’s deadliest viral hemorrhagic fevers, with a case‑fatality rate that can exceed 50 % in untreated patients. The DRC’s latest count of 506 deaths underscores the disease’s lethal potential and the strain on a health system already grappling with conflict‑related disruptions. The outbreak also reverberates beyond Africa: neighboring countries monitor cross‑border movement, and global health agencies allocate resources based on the scale of each flare‑up.

Beyond the immediate health impact, the situation threatens broader socio‑economic stability. Outbreaks typically force school closures, limit market activity, and deter investment in affected regions. Moreover, the reported possibility of a health‑worker strike could cripple case‑finding, contact‑tracing and safe burial practices—key pillars of Ebola containment. A stalled response would likely prolong transmission chains and increase the total death toll.

From a scientific perspective, the pursuit of oral antivirals like NV‑387 could reshape outbreak management. Current treatments, such as monoclonal antibodies, require cold‑chain logistics and infusion by trained personnel, limiting their reach in remote settings. If the gummy proves safe and effective, it could accelerate treatment initiation, reduce hospital stays, and lower transmission risk.

Differing viewpoints and reactions

International partners, including the World Health Organization, have repeatedly urged the DRC government to bolster protective gear and psychosocial support for health workers. The looming strike, as reported by SRN News, reflects a growing frustration among staff who feel that promises of assistance have not materialised.

Conversely, some local officials argue that the threat of industrial action is being amplified by media narratives and that existing resources are being deployed efficiently. They point to the rapid deployment of vaccination campaigns in the most affected health zones as evidence of a coordinated response.

Advocates for experimental therapeutics, represented by NanoViricides, emphasize the need for innovative solutions given the recurrent nature of Ebola in the DRC. Their spokesperson, quoted in Stock Titan, described the oral gummy as “a game‑changer for field‑based care,” though the claim remains unverified pending trial outcomes.

What’s next

The Ministry of Health has pledged to intensify surveillance, expand treatment centre capacity and accelerate vaccination of contacts. A decisive factor will be whether health‑worker grievances are addressed swiftly; a strike could derail these plans.

Clinical testing of the NV‑387 gummy is slated to begin later this year, pending regulatory approval from the DRC’s health authority. If the trial demonstrates safety and efficacy, the product could be rolled out alongside existing monoclonal‑antibody regimens.

International donors are expected to convene a coordination meeting within the next two weeks to reassess funding allocations, with particular attention to personal protective equipment stockpiles and mental‑health services for frontline staff.

Monitoring agencies will continue to update case counts daily, and any further spikes will likely trigger travel advisories from neighboring governments and the United Nations.